Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ABI-007 PLUS GEMCITABINE IN CHINESE PATEINTS WITH METASTATIC PANCREATIC ADENOCARCINOMA

NCT02017015 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02017015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02017015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ABI-007 PLUS GEMCITABINE IN CHINESE PATEINTS WITH METASTATIC PANCREATIC ADENOCARCINOMA
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Completed
Start date
December 24, 2013
Completion date
August 3, 2016
Enrollment
83 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neoplasms